BioCentury | Jul 9, 2007
Company News

MicroIslet board of directors update

...MicroIslet Inc. (MIIS), San Diego, Calif. Business: Endocrine, Gene/Cell therapy Appointed: Keith Hoffman, COO of Thuris Corp....
BioCentury | Jan 17, 2005
Company News

Thuris board of directors update

Thuris Corp. , Irvine, Calif. Business: Neurology Appointed: Jeffrey McKelvy, president and CEO of Avera Pharmaceuticals Inc. WIR Staff Neurology...
BioCentury | Mar 10, 2003
Company News

Sigma-Tau SpA, Thuris deal

...The amended deal includes studying Sigma-Tau's compounds in live animals. Sigma-Tau SpA , Rome, Italy Thuris Corp....
BioCentury | Dec 9, 2002
Company News

Thuris, China National Center for Drug Screening deal

...system creates characteristics of Alzheimer’s disease (AD) and other age-related diseases in animal brain tissue. Thuris Corp....
BioCentury | Oct 14, 2002
Company News

D-Pharm, Thuris deal

...disease (AD) and other age-related diseases in animal brain tissue. D-Pharm Ltd. , Rehovot, Israel Thuris Corp....
BioCentury | Aug 5, 2002
Company News

Praecis, Thuris deal

...AD) and other age-related diseases in animal brain tissue. Praecis Pharmaceuticals Inc. (PRCS), Waltham, Mass. Thuris Corp....
BioCentury | Jul 29, 2002
Company News

Sigma-Tau SpA, Thuris deal

...to identify and develop therapeutics against age-related disease targets in the brain. The deal combines Thuris's...
...Alzheimer's disease (AD) in animal brain tissue with Sigma-Tau's compounds. Sigma-Tau SpA , Rome, Italy Thuris Corp....
BioCentury | Jul 24, 2002
Company News

Thuris, Sigma-Tau neurological deal

...to identify and develop therapeutics against age-related disease targets in the brain. The deal combines Thuris's...
BioCentury | Mar 25, 2002
Finance

Neuro money

...Partners; Working Ventures Canadian Fund; MedTech Partners Warren Pharma Neurological, Ophthalmic, Cardiovascular $5.0 18-Feb-02 BankInvest Thuris...
BioCentury | Feb 4, 2002
Company News

Cephalon, Thuris deal

...will provide Thuris non-exclusive access to enzyme inhibitors that Thuris will evaluate in its assay. Thuris...
...products, and Thuris is eligible for milestones and royalties. Cephalon Inc. (CEPH), West Chester, Penn. Thuris Corp....
Items per page:
1 - 10 of 11
BioCentury | Jul 9, 2007
Company News

MicroIslet board of directors update

...MicroIslet Inc. (MIIS), San Diego, Calif. Business: Endocrine, Gene/Cell therapy Appointed: Keith Hoffman, COO of Thuris Corp....
BioCentury | Jan 17, 2005
Company News

Thuris board of directors update

Thuris Corp. , Irvine, Calif. Business: Neurology Appointed: Jeffrey McKelvy, president and CEO of Avera Pharmaceuticals Inc. WIR Staff Neurology...
BioCentury | Mar 10, 2003
Company News

Sigma-Tau SpA, Thuris deal

...The amended deal includes studying Sigma-Tau's compounds in live animals. Sigma-Tau SpA , Rome, Italy Thuris Corp....
BioCentury | Dec 9, 2002
Company News

Thuris, China National Center for Drug Screening deal

...system creates characteristics of Alzheimer’s disease (AD) and other age-related diseases in animal brain tissue. Thuris Corp....
BioCentury | Oct 14, 2002
Company News

D-Pharm, Thuris deal

...disease (AD) and other age-related diseases in animal brain tissue. D-Pharm Ltd. , Rehovot, Israel Thuris Corp....
BioCentury | Aug 5, 2002
Company News

Praecis, Thuris deal

...AD) and other age-related diseases in animal brain tissue. Praecis Pharmaceuticals Inc. (PRCS), Waltham, Mass. Thuris Corp....
BioCentury | Jul 29, 2002
Company News

Sigma-Tau SpA, Thuris deal

...to identify and develop therapeutics against age-related disease targets in the brain. The deal combines Thuris's...
...Alzheimer's disease (AD) in animal brain tissue with Sigma-Tau's compounds. Sigma-Tau SpA , Rome, Italy Thuris Corp....
BioCentury | Jul 24, 2002
Company News

Thuris, Sigma-Tau neurological deal

...to identify and develop therapeutics against age-related disease targets in the brain. The deal combines Thuris's...
BioCentury | Mar 25, 2002
Finance

Neuro money

...Partners; Working Ventures Canadian Fund; MedTech Partners Warren Pharma Neurological, Ophthalmic, Cardiovascular $5.0 18-Feb-02 BankInvest Thuris...
BioCentury | Feb 4, 2002
Company News

Cephalon, Thuris deal

...will provide Thuris non-exclusive access to enzyme inhibitors that Thuris will evaluate in its assay. Thuris...
...products, and Thuris is eligible for milestones and royalties. Cephalon Inc. (CEPH), West Chester, Penn. Thuris Corp....
Items per page:
1 - 10 of 11